The Importance of Non-vitamin K Antagonists (NOAC) in Their Current Use
Şu kitabın bölümü:
Bilgili,
A.
(ed.)
2023.
Current Researches in Health Sciences-III.
Özet
Non-vitamin K oral anticoagulants are new drugs that are used in the treatment of atrial fibrillation and venous thromboembolism. There are 4 NOACs in use today; dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are Factor Xa inhibitors. NOACs can be used safely in AF patients, except for patients with moderate to severe rheumatic mitral stenosis, and metallic prosthetic valves. In studies where NOACs were evaluated in terms of effectiveness and safety, similar or better results were obtained with VKAs. With the new two antidotes (idaricuzimab and andexanet alfa) approved for use in NOAC-related bleeding, the potential for use of NOACs in patients with high bleeding risk is expected to increase.
Anahtar Kelimeler:
Kaynakça Gösterimi
Lisans
Bu çalışma Creative Commons Attribution 4.0 International License ile lisanslanmıştır.
Yayın Tarihi
DOI
Kategoriler
Telif Hakkı (c) 2023 Ali Bilgili; Fatih Baygutalp- Lale Duysak- Edip Urhan- H. Yeşim Can- Sevil Alkan- Ali Emre Sevik- Buse Keskindağ- Veysel Tosun- Bengü Depboylu- Ege Rıza Karagür- Fatimeh Alghazawi- Bilge Büyükşirin- Büşra Candiri- Amine Nur Arıkan- Sanem Can Çolak- Feride Mehmetoğlu- Ayşe Gülbin Kavak- Merve Gördağ- İ. İlknur Uysal- Aytül Bayraktar- Nastaran Azami- Amirkasra Dehghani- Elif Sibel Aslan- Sajjad Eslamkhah